Study on Trilaciclib and Lurbinectedin for Small Cell Lung Cancer

Sponsor: UNC Lineberger Comprehensive Cancer Center

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05578326

Provider View

This clinical trial is exploring whether the drug Trilaciclib can reduce side effects when used with Lurbinectedin in patients with advanced small cell lung cancer (SCLC) that has not responded to initial treatments.

Patient Parameters

Program Overview

Small cell lung cancer (SCLC) is a very aggressive type of lung cancer and is the leading cause of cancer-related deaths worldwide. The usual first treatment includes a combination of drugs: carboplatin, etoposide, and atezolizumab. While many patients initially respond well to this treatment, the effects often last only about four months. After this, there is no agreed-upon next step for treatment. Lurbinectedin is a drug approved by the FDA and is commonly used as a second treatment option, although it can cause significant side effects, mainly affecting blood cell production. This study is looking at whether adding Trilaciclib can help reduce these side effects and improve the effectiveness of Lurbinectedin in patients with advanced SCLC that has not responded to initial treatments.

Eligibility Criteria

Inclusion Criteria

  • Must provide written consent to participate and allow access to personal health information.
  • Must be 18 years or older.
  • Must be in good general health, able to carry out normal activities or only slightly restricted.
  • Must have cancer that can be measured by scans or tests within 28 days before starting treatment.
  • Must have previously been treated with a platinum-based drug and a PD1 or PDL1 drug.

Exclusion Criteria

  • Cannot have an active infection that requires treatment.
  • Cannot be pregnant or breastfeeding (breast milk cannot be stored for future use during the study).
  • Cannot have taken any experimental drugs within 4 weeks before starting the study treatment.
  • Cannot have known allergies to the study drugs or their ingredients.
  • Cannot be taking any medications or treatments that are not allowed in the study.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.